IGM Biosciences Inc. (IGMS) Tops Q4 EPS by 34c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to IGM Biosciences Inc. (IGMS) Tops Q4 EPS by 34c

IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 30, 2023 4:05 PM EDT

Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial

Imvotamab to move forward into clinical studies in multiple autoimmune diseases

Initiation of Phase 1 clinical trial for targeted immunostimulatory IL-15 cytokine IGM-7354 in patients with solid tumors

   Company to hold conference call and webcast today at 4:30 p.m. EDT   

MOUNTAIN VIEW, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today... More